Introduction
============

Mitochondria are subcellular organelles enriched in energetic tissues, such as muscle and brain, and located in the cytoplasm. Although there are over 1500 human mitochondrial genes (Wallace, [@B68]), only a small fraction of these are directly encoded by the mitochondrial DNA (mtDNA) genome. Human mtDNA, which is inherited in a matrilineal pattern (Giles et al., [@B21]), is a double stranded circular molecule of approximately 16,569 nucleotides (Wallace, [@B68]) containing 37 genes that encode two ribosomal RNAs, 22 transfer RNAs, and 13 polypeptides (Wallace, [@B68]). The current study is of mutations and single nucleotide polymorphisms (SNPs) found only in mtDNA in psychiatric conditions.

One possible indication of a mitochondrial disorder (Wallace et al., [@B69]; Wallace, [@B67]; McMahon et al., [@B40]) is matrilineal inheritance. For neuropsychiatric disorders, higher rates of disease are observed in offspring of maternal probands compared to offspring of paternal probands in SZ (Goldstein et al., [@B22]; Wolyniec et al., [@B72]; Verge et al., [@B66]) and bipolar disorder (BD; McMahon et al., [@B40]). Additionally, previous studies have also shown that mtDNA mutations and variations can play a role of susceptibility to both BD and SZ (Rollins et al., [@B52]; Bertolin et al., [@B9]; Kato et al., [@B29]; Verge et al., [@B66]), suggesting a direct role for the mitochondrial genome in neuropsychiatric disorders (Shao et al., [@B55]). Imaging studies also support the hypothesis that mtDNA alterations lead to neurotransmitter and metabolic changers in BD and SZ (Dager et al., [@B18]; Stork and Renshaw, [@B60]). Failure to find a pattern of maternal inheritance in SZ and BD (DeLisi et al., [@B19]), as well as evidence for the role of paternal inheritance have also been reported in family studies (Kornberg et al., [@B34]). Researchers have previously speculated that parent-of-origin effects might reflect subtle ascertainment biases, imprinting, X-linked genetic factors, vertical transmission of infectious agents, and *in utero* or other early maternal influences on offspring (McMahon et al., [@B39]).

Somatic mutations that arise during aging in brain and variation in length of mtDNA have been reported for select regions of the mtDNA genome (Cortopassi and Arnheim, [@B14], [@B15]; Cortopassi et al., [@B17]; Soong et al., [@B59]; Cortopassi and Hutchin, [@B16]; Hutchin and Cortopassi, [@B25]). mtDNA is particularly susceptible to a higher rate of somatic deletions because mtDNA is not protected by histones and lacks the complete set of DNA repair machinery associated with nuclear DNA. Mutation rates are higher in mtDNA compared to nuclear DNA, and mutation rates are particularly high in non-coding regions of the mtDNA in human brain such as the hypervariable region of the mtDNA genome (Jazin et al., [@B28]; Cavelier et al., [@B12]). The accumulation of mtDNA mutations is tissue-specific, believed to be proportional to metabolic rate (Shoffner and Wallace, [@B57]) and could be a result of increased reactive oxygen species (ROS) in mitochondria. Oxidative stress and accumulation of ROS have also been observed in BD and SZ, suggesting a role for mitochondrial dysfunction in those disorders (Ben-Shachar, [@B7]; Rezin et al., [@B51]; Wood et al., [@B73]; Bitanihirwe and Woo, [@B10]; Pickrell et al., [@B48]; Verge et al., [@B66]).

Previously, our group and others have studied the mtDNA association with SZ and BD cases in a small number of subjects, and these case-control analyses of mtDNA SNPs have focused on rare mutations or haplogroup-defining SNPs and have not found compelling evidence for association (Shao et al., [@B55]; Rollins et al., [@B52]), although a recently large mitochondria SNP (mtSNP) study reported no excess prevalence of SZ in major European haplogroups (Mosquera-Miguel et al., [@B43]). In our previous study we used a re-sequencing array to study mtDNA in the dorsolateral prefrontal cortex (DLPFC) of SZ, BD, and major depressive disorder (MDD) patients and observed an increase of synonymous substitutions in SZ (Rollins et al., [@B52]). Recently, another group also used a re-sequencing array to study mtDNA in blood samples from patients with SZ and BD but did not find additional evidence that mtDNA contributes significantly to the maternal component of SZ and BD predisposition (Bertolin et al., [@B9]). To date, few studies have examined somatic mutations in multiple regions, and most studies have concentrated on DLPFC only (Shao et al., [@B55]). However, other regions have been shown to be particularly susceptible to mitochondrial alterations in oxidative phosphorylation such as the striatum and the substantia nigra (SN; Pickrell et al., [@B48]; Surmeier et al., [@B61]).

The relationships between a common somatic mtDNA variation, a 4977 bp deletion (Cortopassi et al., [@B17]; Soong et al., [@B59]), and age, sex, and diagnosis (Shao et al., [@B55]) was also tested in several brain regions and blood (cohorts 1 and 2). We hypothesized that psychiatric disorders (BD, MDD, and SZ) would have increased common deletion compared to controls after adjusting for the strong effect of age. The present study surveyed mtDNA SNPs in a total of 11 brain regions and in blood DNA samples by next generation sequencing to determine the influence of genetic variation in psychiatric disorders (cohort 3). Finally, mtDNA SNPs from the Affymetrix 6.0 SNP chip were tested in blood for association with SZ, BD, or both, using the Genetic Association Information Network (GAIN; SZ, BD, and controls) and Wellcome Trust Case Control Consortium 2 (WTCCC2) controls comprising a cohort of 6,040 EA cases and controls. The controls from GAIN and WTCCC2 were combined, and duplicate control subjects in GAIN were excluded in this analysis.

Materials and Methods
=====================

Post-mortem brain samples
-------------------------

Informed consent was obtained from the next of kin for each subject and the study was reviewed and approved by the University of California, Irvine (UCI) Institutional Review Board. Three brain tissue cohorts were processed. Cohort 1 consisted of 11 subjects (6 controls, and 5 cases with schizophrenia) with 11 brains regions per subject (121 samples in total; Table [1](#T1){ref-type="table"}), this cohort was used for the mitochondrial common deletion assay. Cohort 2 was comprised of 76 DLPFC samples from BD, MDD, SZ, and controls subjects (Table [1](#T1){ref-type="table"}) that was used for the common deletion assay with no overlap between cohort 1 and 2 subjects. Cohort 3 was comprised of 23 DLPFC samples (four BD, five MDD, four SZ, and 10 controls) that were used for mitochondrial whole genome sequencing. Five of the 10 control subjects from cohort 3 were re-sequenced in 10 additional brain regions, and three were also re-sequenced in blood (74 samples in total; Table [1](#T1){ref-type="table"}). Cohorts 1 and 3 shared five controls in common.

###### 

**Clinical and demographic characteristics for cohorts 1, 2, and 3/cohort 1 (*n* = 11) diagnosis and age**.

  Diagnosis                                     Sex (male/female)   Age (mean ± SD)
  --------------------------------------------- ------------------- -----------------
  **COHORT 1**                                                      
  SZ                                            2/3                 53 ± 7
  Control[\*](#tfn1){ref-type="table-fn"}       2/4                 57 ± 27
  Total                                         4/7                 
  **COHORT 2**                                                      
  BD                                            9/3                 50 ± 17
  MDD                                           11/4                51 ± 15
  SZ                                            11/3                44 ± 10
  Control                                       29/6                53 ± 12
  Total                                         60/16               
  **COHORT 3**                                                      
  BD                                            3/1                 57 ± 8
  MDD                                           4/1                 41 ± 14
  SZ                                            2/2                 41 ± 9
  Control**[\*](#tfn1){ref-type="table-fn"}**   7/3                 52 ± 23
  Total                                         16/7                

*The 4,977 bp mtDNA common deletion percentage was measured in 11 brain regions. Cohort 2 was used in the assay for mtDNA common deletion (4,977 bp) of 76 DLPFC samples. Cohort 3 was used for Illumina re-sequencing of mtDNA in 23 DLPFC samples. Five control subjects were completely re-sequenced in 11 brain regions, three subjects also had blood re-sequenced (ages 53, 64, and 103 years old)*.

*\*Five overlapping control subjects from Cohort 1 shown in Table S1 in Supplementary Material were included in this cohort*.

Brain dissections
-----------------

For cohort 1, DNA was extracted from the following tissues: anterior cingulate cortex (ACC), amygdala (AMY), caudate nucleus (CAUN), cerebellum (CB), DLPFC, hippocampus (HIPP), nucleus accumbens (NACC), orbitofrontal cortex (OFC), putamen (PUT), SN, and thalamus (THAL) for 11 subjects and whole blood was obtained for three of those subjects. Briefly, prefrontal cortex samples were dissected from orbital gyrus (OFC) and the dorsal lateral prefrontal cortex at the level of the anterior end of the corpus callosum. The ACC was sampled just above the most anterior part of the corpus callosum. Three striatal structures (CAUN, putamen, and NACC) were dissected from the same coronal slice at a level where the three structures were visible anterior to the anterior commissure. The amygdala was sampled from the temporal lobe, ventral to the putamen just anterior of the hippocampus. The whole hippocampus and parahippocampal gyrus were dissected from the subsequent posterior coronal slices as a block and sampled together. The SN and the whole thalamus (from the lateral ventricle to the medial lemniscus and from the internal capsule to the midline of the brain), were individually dissected from the same coronal slice. Finally, a cortical sample of the lateral left cerebellum was dissected for processing and quality control. DNA was extracted from 25 mg of dissected brain tissue using a DNeasy Blood and Tissue Kit (Qiagen), according to the manufacturer's protocol. For cohort 2 DNA was extracted from 76 DLPFC samples using the phenol phase of a Trizol protocol and precipitated with ethanol (Shao et al., [@B55]). Cohort 2 samples were assayed for the common deletion using copy number standards to quantitatively validate previous findings.

Mitochondrial common deletion quantification
--------------------------------------------

Primers were designed targeting the deleted or non-deleted region around the region of the deletion spanning mt8224--13501. As described previously (Shao et al., [@B55]), these primers allow the specific amplification of the deleted and non-deleted version of the mtDNA. A 300 bp amplicon was detected by quantitative polymerase chain reaction (qPCR) only in the presence of the common deletion, which occurs from mt8470 to 13447, by using a forward primer that binds to the flanking region. Primers for the 325 bp non-deleted amplicon spanned mt13176--13501 and the amplicon was detected only in the absence of the common deletion. Eight linearly diluted copy number standards were created from clones of the deletion or non-deletion amplicon and each clone was sequenced verified for presence of the correct insert.

Quantitative polymerase chain reaction was performed using the 7900 Sequence Detection System (Applied Biosystems) with cloned standards that ranged from 1,000,000 to 100 copies/μl, and the SYBR Green chemistry (Applied Biosystems). Two separate reactions were run for the deleted and non-deleted amplicon detection. The ABI Prism 7900 Sequence Detection System default thermal cycler program was used for each reaction: 10 min of pre-incubation at 95°C followed by 40 cycles of 15 s at 95°C and 1 min at 60°C. Individual real-time PCR reactions were performed in duplicate in a total volume of 12.5 μl in 384-well plates (Applied Biosystems) containing 6.25 μl SYBR Green (Applied Biosystems), 2.5 μl DNA (10 ng/μl), or 2.5 μl standards, 0.25 μl forward and reverse primers (10 pmol/μl), and 3.25 μl H~2~O. The cycle threshold (CT) was manually set at the level that reflected the best kinetic PCR parameters. Using the copy number standard curve, CT values were used to calculate copy number for the deleted and non-deleted amplicons: percent common deletion = (deletion copy number)/(deletion copy number + non-deletion copy number) × 100 (Shao et al., [@B55]). This equation estimates the percentage of common deletion normalized to the total number of mitochondrial copies present in a given sample. Common deletion levels showed a normal distribution across brain regions therefore we adopted parametric comparisons for region, age, and diagnosis effects. The common deletion amplicons were confirmed by gel electrophoresis to make sure only one fragment was amplified and by direct sequencing to assure specificity. The mitochondrial common deletion was assayed in two cohorts of subjects (cohorts 1 and 2). For cohort 1, the effect of age was estimated by linear regression and repeated measures ANOVA was used to analyze the effects of 11 brain regions (the within subjects measure), sex, and diagnosis on age-adjusted residuals. For cohort 2, the DLPFC data was analyzed by ANCOVA, with age as a covariate and sex and diagnosis as factors (Statistica 9.1, Tulsa, OK, USA).

Cloning common deletion and wildtype amplicons
----------------------------------------------

Non-deleted and deletion-specific fragments were amplified by PCR and gel purified according to the QIAquick Gel Extraction Kit protocol (Qiagen) and TA cloned using the Original TA Cloning Kit (Invitrogen). The ligation reaction consisted of 1 μl PCR product (2.60 ng), 1 μl 10× ligation buffer, 2 μl PCR 2.1 vector (25ng/μl), 5 μl H2O, and 1 μl T4 DNA ligase run at 14°C overnight. Two μl of each ligation reaction was pipetted into a 50 μl vial of frozen One Shot competent cells (Invitrogen) per sample and heat shocked for 30 s at 42°C. After cooling the vials on ice, S.O.C. medium (Invitrogen) was added to each vial and 10--50 μl from each transformation vial was spread on LB agar plates containing 60 μg/ml X-gal and 50 μg/ml of kanamycin (Teknova). Plates were incubated overnight at 37°C and white colonies were selected and grown overnight at 37°C in a 2--5 ml LB broth tube containing 50 μg/ml kanamycin (Teknova). The plasmid containing the amplicon was extracted using a PureLink Quick Plasmid MiniPrep Kit (Qiagen). The plasmid was amplified and the samples were run on a 1% agarose gel and sequenced to confirm the presence of the correct amplicons. To further validate the qPCR amplicons, randomly selected qPCR amplicon reactions from the deletion and non-deletion assay plates were sequenced (Genewiz, Inc.; Ann Arbor, MI, USA). QPCR products for sequencing were run on a 1% agarose gel, purified using a QIAquick Gel Extraction Kit (Qiagen), and 10 ng DNA was mixed with 5 μl forward deletion or non-deletion specific forward primers (5 μM) in a total volume of 15 μl for capillary sequencing.

Mitochondrial whole genome sequencing for homoplasmic mutations
---------------------------------------------------------------

Mutations were identified in 11 brain regions and blood (cohort 1) and in a separate cohort (cohort 3) of a single brain region (DLPFC) in subjects with SZ, BD, MDD, and controls by Illumina GAII sequencing. DNA (50 ng) was used to amplify the entire mitochondrial genome in two overlapping fragments of 9,289 bp (I) and 7,626 bp (II) in length. The primer sequences used to amplify fragment (I) are 5′-AACCAAACCCCAAAGACACC-3′ and 5′-GCCAATAATGACGTGAAGTCC-3′. The primer sequences for fragment (II) are 5′-TCCCACTCCTAAACACA TCC-3′ and 5′-TTTATGGGGTGATGTGAGCC-3′. PCR reactions, 50 μl using TaKaRa LA Taq polymerase, were performed with the following cycling conditions: 95°C 2 min; 35 cycles of 95°C 20 s, 59°C 30 s, 68°C 10 min; 68°C 20 min. PCR reactions were electrophoresed on 0.8% TAE agarose gels at 120 V. Fragments were gel extracted using the QIAquick gel extraction kit (Qiagen) and eluted in 30 μl elution buffer. Eluted samples were measured using the SpectraMax Plus 384 microplate spectrophotometer (Molecular Devices). The parallel DNA sequencing was performed using the Illumina Genome Analyzer II at Ambry Genetics Corporation (Aliso Viejo, CA, USA) according to the manufacturer's protocol. Briefly, pooled, amplified mtDNA samples (fragments I and II) were sonicated and fragment ends were repaired and phosphorylated using Klenow T4 DNA polymerase and T4 polynucleotide kinase. An A base was added to the 3′ end of the blunted fragments and the resulting fragments were ligated to custom index adapters. The ligated products were size selected by gel purification and then PCR amplified. Using the Agilent Bioanalyzer (Santa Clara, CA, USA), each library size and concentration was determined so that samples were combined at equal molar ratios and multiplexed at 16 libraries per lane in a flow cell. This approach allows the purification of mtDNA from genomic DNA but has the disadvantage of excluding deleted mtDNA molecules.

Alignment to the reference and consensus sequence
-------------------------------------------------

Illumina GAII single reads were aligned to the mitochondrial revised Cambridge Reference Sequence (rCRS; GenBank accession number NC_012920; Andrews et al., [@B2]) using Illumina's Efficient Local Alignment of Nucleotide Data (ELAND) algorithm (Bentley et al., [@B8]). The consensus sequence was built using the reads aligned with ELAND using in-house software developed at the Institute for Genomics and Bioinformatics of the University of California, Irvine. A read was considered as successfully aligned to a given position of the reference sequence if the number of mismatches between the read sequence and the reference sequence was strictly lower than three. Reads with more than two mismatches with the reference sequence were rejected and considered as not aligned to the reference sequence. For each sample, around 90% of the reads were successfully aligned with the NC_012920 reference sequence for the entire human mtDNA genome. A phylogenetic tree was constructed from the consensus sequences according to PhyloTree[^1^](#fn1){ref-type="fn"} Build 12 (van Oven and Kayser, [@B65]).

The Illumina sequencing data was screened for novel or rare homoplasmic variants using the following criteria: (1) coverage for a position was greater than 500×, the called allele was not the reference allele, (2) the% call at the variant position was \>96%, and (3) the mutation had a reported incidence less than 1% in PhyloTree Build 12 (van Oven and Kayser, [@B65]), or in a total of 5,102 downloaded sequences from GenBank, or the mtDB-Human Mitochondrial Genome Database (Ingman and Gyllensten, [@B26]). The mutation data was further screened at MitoMap (Ruiz-Pesini et al., [@B53]) for submitted and unpublished mutations and disease associations. We further validated the observed variants by comparing for the same subjects different brain regions and also confirmed new or novel mutations by allele-specific PCR and by the dye-terminator sequencing method.

Association study of mtSNPs
---------------------------

The GAIN datasets were obtained from the database of Genotypes and Phenotype (dbGaP). Data access was granted by the GAIN Data Access Committee for analysis of an approved project "Genetic Variation in Mitochondria in Schizophrenia and Bipolar Disorder." The WTCCC2 cohort was obtained by Fabio Macciardi and Sara Lupoli. A certain number of control samples were shared between the GAIN cohorts; we made sure that there was no overlap between the cohorts and that only unique control subjects were included in the final analysis. Further, we used a common control group consisting of pooled WTCCC2 and GAIN samples to compare against BD and SZ subjects from GAIN. The subjects from GAIN chosen for inclusion in the analysis were controls (general research consent use, GRU), subjects with schizophrenia and related conditions (SARC), and bipolar subjects (bipolar disorder only, BDO; bipolar and related disorders, BARD), demographic details and distribution per cohort are showed in Table S1 in Supplementary Material. In order to minimize population specific mtDNA variants that would confound case-control analysis, African Americans were not included in the mtDNA analysis and individuals of European ancestry (EA) were analyzed. Affymetrix 6.0 SNP CEL files were extracted for 465 mtSNPs using Affymetrix Power Tools scripts (available upon request from author) and annotated at NetAffx[^2^](#fn2){ref-type="fn"}. In brief, median normalization for perfect match probes was used with a Birdseed (version 2) algorithm on 465 mtSNPs annotated from NetAffx (Korn et al., [@B33]). The output was forced for allele call only. After the mitochondria allele calls were determined for 465 SNPs and annotated with NetAffx, these 465 mtSNPs were pruned to 362 SNPs by removing SNPs with a no call rate \>5% and individual subjects with \<95% call rates. A genetic distance hierarchical clustering was performed to see whether site of origin (GAIN vs. WTCCC2) of control DNA potentially stratified the data, however this effect did not appear. Multidimensional scaling (MDS) analysis and logistic regression were calculated in PLINK with mtSNPs (Purcell et al., [@B50]) using four MDS covariates. The logistic regression results were compared with the Ingman database of mtSNP frequencies to remove outlier nominally significant associations due to obvious miscalls with the Affymetrix genotyping platform. There has not been a previous association study of mtDNA SNPs in psychiatry that has the same power as the present study; we calculated a 99% power to detect a 5% allelic difference.

Results
=======

Common deletion in human brain increases with age
-------------------------------------------------

We measured the levels of the common 4977 bp deletion across all brain regions in cohort 1. We observed, in a multivariate analysis, that age was significantly correlated with common deletions levels, *R*^2^ for age and common deletion calculated for 11 brain regions can be seen in Table S2 in Supplementary Material (*p* = 0.024). The most significant individual brain regional correlations with age were observed in the NACC, CAUN, and AMY (Figures [1](#F1){ref-type="fig"}A--C) for cohort 1; the additional figures for the other brain regions can be seen in Figure S1 in Supplementary Material. Common deletion percentages for individual regions were significantly correlated with age in seven regions, while four regions did not show significant Pearson correlations (Table S3 in Supplementary Material). The regional correlation matrix of the common deletion shows nominally significant (*p* \< 0.05) relationships of the common deletion between brain regions for 31 pair wise correlations of 55 pairs. Thus, slightly over half of these paired brain regions show significant correlations for accumulation of the common deletion with age.

![**The highest correlations between the common deletion and age are shown for cohort 1 subjects**. **(A)** The correlation between age (*x*-axis) and mtDNA common deletion (*y*-axis) showing the nucleus accumbens (NACC), *r* = 0.97. **(B)** The correlation between age (*x*-axis) and mtDNA common deletion (*y*-axis) showing caudate nucleus (CAUN), *r* = 0.98. **(C)** The correlation between age (*x*-axis) and mtDNA common deletion (*y*-axis) showing amygdala (AMY), *r* = 0.96.](fgene-03-00103-g001){#F1}

The highest levels of the common deletion were observed in regions that have origins in the mesencephalon (SN) and telencephalon (CAUN). Overall, common deletion levels were greatest in mesencephalon (SN) \> telencephalon (CAUN, putamen, NACC, cortical regions) \> diencephalon (thalamus) ( rhomboencephalon (cerebellum). An ongoing study that includes over 500 samples will be used to independently retest these correlations of the common deletion across all brain regions. The OFC showed the highest number of significant correlations to all other brain regions of common deletion, in fact was significantly correlated to all other 10 regions (Table S3 in Supplementary Material).

A repeated measures ANCOVA was also performed for the common deletion with age as a covariate, region as a repeated measure factor, and sex and diagnosis as between-subjects factors for cohort 1. There was a significant overall effect of region \[*F*(9, 63) = 6.49; *p* = 1.7 × 10^−06^\], while sex \[*F*(1, 6) = 0.39; *p* = 0.55\], and diagnosis \[*F*(1, 6) = 3.73; *p* = 0.10\] factors were not significant, and interaction terms were not statistically significant (Figure [2](#F2){ref-type="fig"}). The significant region effect was further examined by *post hoc* comparisons of the mean percentage of common deletion per brain region and *p*-values were corrected for multiple comparisons using Tukey's Honest Significant Difference test for each regional-comparison (AMY, ACC, CAUN, CB, DLPFC, HIPP, NACC, OFC, PUT, SN, and THAL). The two regions with the highest levels of common deletion were the CAUN and SN, with a 39- to 40-fold increase compared to the CB, which had the lowest common deletion level (Figure S2 in Supplementary Material) which is consistent with earlier reports (Corral-Debrinski et al., [@B13]; Soong et al., [@B59]; Meissner et al., [@B41]). These three regional differences account for most of the significant *post hoc* differences observed, while the remaining regions were not significantly different when corrected for multiple comparisons (Table S4 in Supplementary Material). The mtDNA common deletion percentage was 0.5 ± 0.4 SEM for blood (*n* = 3), but was greatly increased in the brain for the same subjects, consistent with prior observation of low common deletion levels in blood and higher levels in post mitotic tissue.

![**There was no overall region × diagnosis (schizophrenia compared to control) interaction effect on age-adjusted mtDNA common deletion percentages but regional differences were observed**. This figure shows the least squares mean and standard errors of non-age-adjusted common deletion percentages per region, plotted by diagnosis in cohort 1 (schizophrenia compared to controls).](fgene-03-00103-g002){#F2}

Results of the common deletion study in DLPFC only (cohort 2) showed also a significant relationship between age and common deletion levels (*F* = 6.7, *p* = 0.01), (Figure S3 in Supplementary Material) as well as sex and common deletion (*F* = 5.5, *p* = 0.02; Figure [3](#F3){ref-type="fig"}A). Our hypothesis that psychiatric disorders (BD, MDD, and SZ) have increased common deletion was tested in a planned comparison of the age-adjusted data in DLPFC (cohort 2). The BD group showed a significant increase in the common deletion compared to controls (*p* = 0.022, Figure [3](#F3){ref-type="fig"}B) by a fold change of 2.4 using age-adjusted least square means, MDD showed a 2.0 fold increase compared to controls (*p* = 0.058), while SZ was not significantly different compared to controls (*p* = 0.59). These findings validated previous data for BD and MDD for the same subjects in cohort 2 (Shao et al., [@B55]), however in the present study we used a more accurate method using a standard curve. Thus, we show increased mtDNA common deletion in BD, no change in SZ or MDD, compared to controls in DLPFC.

![**(A)** In cohort 2, the main effect of sex was significant (*F* = 5.5, *p* = 0.02) on common deletion percentage in DLPFC, with females exhibiting significantly higher percentages of the mitochondrial common deletion compared to males. The age-adjusted means and standard error bars are displayed.**(B)** In cohort 2, the BD group showed a significant increase in the common deletion compared to controls (*p* = 0.022) and MDD showed a trend compared to controls (*p* = 0.058) while schizophrenia compared to controls was not different (*p* = 0.59).](fgene-03-00103-g003){#F3}

Homoplasmic novel and rare variants in mtDNA
--------------------------------------------

There were 149 homoplasmic variants that were either novel or rare found by Illumina re-sequencing (Table S5 in Supplementary Material): 88% (131/149) were transitions, 11% (17/149) were transversions (Table S6 in Supplementary Material). Of these 149 homoplasmic variants, seven were novel and not reported in four databases: dbSNP (Sherry et al., [@B56]), mtDB (Ingman and Gyllensten, [@B26]), PhyloTree (van Oven and Kayser, [@B65]), and MITOMAP[^3^](#fn3){ref-type="fn"}. Six of the novel variants were in coding genes, five were synonymous, one was in a transfer RNA; one was in the non-coding D-Loop region (Table [2](#T2){ref-type="table"}) and these were not found in an analysis of 5140 human mtDNA genomes (Pereira et al., [@B47]). We selected and successfully confirmed by dye-terminator direct sequencing of the following five variants: C4796T, G4924C, A6578G, T8945C, and A11026G.

###### 

**Novel mitochondrial homoplasmic mutations (7) found in brain of neuropsychiatric patients and controls detected with Illumina sequencing**.

  Position   Gene       Function   rCRS Base   Mutation   AA change   Syn/non-syn   Tissue                                                      Diagnosis   In Mitomap   Validated by Sequencing
  ---------- ---------- ---------- ----------- ---------- ----------- ------------- ----------------------------------------------------------- ----------- ------------ -------------------------
  224        D-loop     nc         T           T \> C                               DLPFC                                                       MDD         No           
  5686       tRNA Asn   ps         A           A \> T                               ACC, AMY, CAUN, CB, DLPFC, HIPP, NACC, OFC, PUT, SN, THAL   C           No           
  6578       COI        pp         A           A \> G     225G \> G   SYN           DLPFC                                                       C           No           Yes
  7834       COII       pp         C           C \> T     83I \> I    SYN           DLPFC                                                       SZ          No           
  9126       ATPase 6   pp         T           T \> A     200T \> T   SYN           DLPFC                                                       C           T \> C       
  10858      ND4        pp         T           T \> C     33I \> I    SYN           DLPFC                                                       BD          No           
  11026      ND4        pp         A           A \> G     89L \> L    SYN           DLPFC                                                       C           No           Yes

*All attempted direct sequencing validations were successful. Subjects shown with 11 brain regions (cohort 1) and DLPFC (cohort 3) were tested*.

Only one homoplasmic deletion was detected, an AC deletion at mt523-524, present in 11 brain regions sampled from two control subjects that have distant haplogroups (L1cb2 and H5, Figure [4](#F4){ref-type="fig"}). This mt523-524 AC deletion was previously reported (Han et al., [@B23]; Wanrooij et al., [@B71]). Two homoplasmic insertions were detected. One control subject had a T insertion at mt455. A second common insertion was also observed in the mononucleotide repeat (poly-C) region known as D310 for Displacement Loop (D-Loop), which consists of a series of C nucleotides (between 7 and 9) intercalated with a single T at position 310 followed by another series of C nucleotides (Sanchez-Cespedes et al., [@B54]), a hot spot for mutations possibly involved in Alzheimer's (Wang et al., [@B70]), and cancer (Tang et al., [@B63]). Six subjects (three controls, two BP, and one SZ) had 309.1C or 309.1CC insertions in this poly-C tract. Due to the small number of subjects in this re-sequencing arm of the study, the rates of *de novo* mutations were not compared among groups. In summary, there were seven novel mutations in Cohort 3: four novel mutations in the 10 control subjects, one novel mutation in the four SZ subjects, one novel mutation in the five MDD subjects, and one novel mutation in the four BD subjects.

Considering further the rate of novel coding and non-coding mutations in cohort 3 (23 DLPFC subjects), there was one novel mutation in the non-coding region of the mitochondrial genome, resulting in a novel mutation frequency of 3.87 × 10^−5^ (23 genomes × 1121 bp non-coding = 25,783 total non-coding bp, one mutation/25,783 bp = 3.87 × 10^−5^ or 1:25,783; Table S7 in Supplementary Material). There were six novel mutations in the coding region for these subjects leading to a 1.69 × 10^−5^ novel mutation frequency (23 genomes × 15,447 bp total coding sequence = six novel mutations per 35,5281 bp or 1:59,214). These calculations show that novel mutations occurred more frequently in the non-coding region of the mitochondria compared to the coding region.

A total of 142 of the 149 variants were rare (Table S5 in Supplementary Material) with minor allele frequency \<1% based upon mtDB (Ingman and Gyllensten, [@B26]) and PhyloTree (van Oven and Kayser, [@B65]). We observed a higher number of both transitions and transversions per genome for the MDD group compared to controls and to the other two diagnoses particularly in the non-coding region, yet had fewer transversions in the coding region, resulting in a higher ratio of transitions over transversions in the coding region (Table S8 in Supplementary Material).

Phylogenetic analysis of mtDNA from brain
-----------------------------------------

We conducted phylogenetic analysis using the consensus sequence of the whole mitochondrial genome which allowed us to determine the specific haplogroup for each sample (van Oven and Kayser, [@B65]). All brain regions for each individual subject were correctly grouped together showing the accuracy and consistency of our sequencing algorithms (Figure [4](#F4){ref-type="fig"}). The distribution of diagnoses for each haplogroup built using the entire mtDNA consensus sequences can be seen in Table S9 in Supplementary Material. We detected back mutations in the haplogroups shown in Figure [4](#F4){ref-type="fig"}. Notably, the mtDNA sequence of individual 58 allowed us to refine the mutation motif of haplogroup L1c3b2, which thus far was based on a single mtDNA sequence only (Behar et al., [@B4]), viz. sequence 597 from (Howell et al., [@B24]). When we detected a homoplasmic mutation or rare variant in one brain region, it was inevitably found in the remaining 10 brain regions (Figure [4](#F4){ref-type="fig"}).

![**Phylogenetic tree of the 23 complete mtDNA sequences generated in this study**. Haplogroups are labeled in boxes and follow PhyloTree Build 12 nomenclature (van Oven and Kayser, [@B65]). Mutations are denoted as nucleotide position numbers corresponding to the rCRS. Mutations are transitions unless an exact base change is specified. Deletions and insertions are indicated by "d" and "0.1," respectively, followed by the base(s) involved. Back mutations (from the perspective of the ancestral root) are preceded by "@." Variants 309.1C, 315.1C, 16182C, 16183C, and 16519 were not considered for tree construction and are therefore not shown. The samples that have appeared in the study are given numerical labels followed by brain region abbreviations. As an example, in the first column individual 58, belonging to haplogroup L1c3b2, was sequenced in 11 brain regions which all showed the same phylogenetic relationship, indicating a lack of novel mutations between brain regions from the same individual.](fgene-03-00103-g004){#F4}

mtSNP association in psychiatric disorders
------------------------------------------

PLINK logistic regression was run with genotypes for 362 mtSNPs from 6,040 subjects using MDS covariates. In all analyses, the overlap of SZ and BD controls from the GAIN study were removed before undertaking association or normalization.

The GAIN and WTCCC2 controls were pooled into one common control group for comparison to BD and SZ subjects from GAIN. There were no significant mtSNP associations with psychiatric disorders after genome-wide correction. However, the logistic regression analysis showed nominally significant association with SZ, BD, and pooled analysis for nine different mtSNP alleles that passed nominal threshold of *p* \< 0.05 for SZ or BD association (Table [3](#T3){ref-type="table"}) without correction for multiple testing. Some of these nominally associated mtSNPs were located in mutation hotspots in the hypervariable I (between positions 16001 and 16568) and II (between positions 1 and 574) regions (Table [4](#T4){ref-type="table"}). The remaining associated coding mtSNPs were primarily synonymous. MtSNPs with relatively low no call rates compared to MAF were included in Table [4](#T4){ref-type="table"}. The "no calls" are from the Affymetrix 6.0 SNP chip analysis, for an individual SNP when the algorithm is unable to assign an allele call. The listing of additional SNPs that had nominal *p*-value for association, but had high no call rates is shown (Table S10 in Supplementary Material). Interestingly, the minor population allele showed an equal number of risk and protective associations for psychiatric disorders (Table [4](#T4){ref-type="table"}).

###### 

**mtDNA SNPs from Affymetrix cel files were used to calculate association with MDS covariates**.

  Case-control    SNP affymetrix ID   dbSNP RS ID   rCRS pos   Mutation                                  Risk allele   *n*    OR     STAT     *p*
  --------------- ------------------- ------------- ---------- ----------------------------------------- ------------- ------ ------ -------- -------
  BD              SNP_A-8574923       rs28357968    3666       G3666A                                    A             4900   1.81   2.328    0.020
  BD              SNP_A-8574914       rs28357375    15784      T15784C                                   C             4902   1.49   1.982    0.048
  SZ              SNP_A-8574733       rs2857291     195        T195C[\^](#tfn2){ref-type="table-fn"}     T             4965   0.82   −3.547   0.000
  SZ              SNP_A-8574778       rs3937033     16519      T16519C                                   C             5039   0.92   −2.131   0.033
  SZ + BD         SNP_A-8574733       rs2857291     195        T195C[\^](#tfn2){ref-type="table-fn"}     T             5896   0.87   −3.375   0.001
  SZ + BD         SNP_A-8574923       rs28357968    3666       G3666A                                    A             6037   1.58   2.051    0.040
  SZ + BD         SNP_A-8574991       rs28380140    9377       A9377G[\^](#tfn2){ref-type="table-fn"}    A             6040   0.46   −2.046   0.041
  SZ + BD         SNP_A-8574741       rs3088053     11812      A11812G[\^](#tfn2){ref-type="table-fn"}   A             6015   0.86   −2.086   0.037
  SZ + BD         SNP_A-8574553       rs2853497     12007      G12007A[\^](#tfn2){ref-type="table-fn"}   G             6040   0.77   −2.098   0.036
  **Case-case**                                                                                                                               
  BD vs. SZ       SNP_A-8574692       rs2853515     263        A263G                                     A             2094   1.76   2.3      0.021
  BD vs. SZ       SNP_A-8574530       rs1599988     4216       T4216C                                    C             1994   1.71   2.451    0.014
  BD vs. SZ       SNP_A-8574778       rs3937033     16519      T16519C                                   T             2098   1.11   2.02     0.043

*Nominally significant SNPs for association with pooled groups (BD + SZ), BD, and SZ are shown*.

*For the additive effects of SNPs, a positive odds ratio (OR) means that the minor allele increases risk for phenotype*.

*\^Indicates that the minor allele increases protection against risk*.

###### 

**Annotation of nominally significant SNPs from association with pooled groups (BD + SZ), BD, and SZ are shown**.

  Case-control     Risk allele   Posn.   Base   A            G            C             T             Location   Amino Change   Syn?
  ---------------- ------------- ------- ------ ------------ ------------ ------------- ------------- ---------- -------------- ------
  BD               A             3666    G      **58 (R)**   2646                                     ND1        Gly → Gly      Yes
  BD               C             15784   T                                **85 (R)**    2619          Cytb       Pro → Pro      Yes
  SZ               T             195     T      11                        **280 (P)**   1574          D-Loop                    
  SZ               C             16519   T                                1115          **752 (P)**   D-Loop                    
  SZ + BD          T             195     T      11                        280 (P)       1574          D-Loop                    
  SZ + BD          A             3666    G      58 (R)       2646                                     ND1        Gly → Gly      Yes
  SZ + BD          A             9377    A      2661         **43 (P)**                               COIII      Trp → Trp      Yes
  SZ + BD          A             11812   A      2616         88 (P)                                   ND4        Leu → Leu      Yes
  SZ + BD          G             12007   G      96 (P)       2608                                     ND4        Trp → Trp      Yes
  **Case--case**                                                                                                                
  BD vs. SZ        A             263     A      6 (R)        1861                                     D-Loop                    
  BD vs. SZ        C             4216    T                                **244 (R)**   2460          ND1        Tyr → His      No
  BD vs. SZ        T             16519   T                                1115          **752 (R)**   D-Loop                    

*The position is according to revised Cambridge Reference Sequence (Posn.), and numbers of individuals world-wide from Ingman database for each allele are shown. The bolded minor allele shows an R for risk or P for protection according to the association results in Table [3](#T3){ref-type="table"}. As an example, for T16519C, there is an increase frequency of T in BD (0.51) compared to SZ (0.4), and decreased frequency of T in SZ compared to C (0.49). The actual case and control counts are shown in Table S11 in Supplementary Material*.

The haplogroup-defining SNP (A12308G) and the T195C allele in D-Loop region were combined in an exploratory *post hoc* analysis (Table [5](#T5){ref-type="table"}) by using a Cochran-Mantel-Haenszel test for repeated 2 × 2 tests of independence. The SZ group showed less 195C alleles than controls (CMH = 10.6, df = 2, *p* = 0.0011), while similar test conducted for BD was not significant (CMH = 2.6, df = 2, *p* = 0.10); however, the combined SZ + BD CMH was significant (*p* = 0.001). These results confirm the under-representation of the 195C allele in SZ, independent of a major ethnic stratification of SNP A12308G. The 195C allele was associated with a reduced relative risk in controls by 0.67--0.80 depending on the A12308G allele call.

###### 

**The haplogroup defining SNP (A12308G) and the T195C allele in D-Loop region were tested in a *post hoc* analysis using a Cochran--Mantel--Haenszel (CMH) test for repeated 2 × 2 tests of independence**.

  mtDNA allele   Group                               
  -------------- --------------- ------ ------------ --------
  A              T               2600   761          629
                 C               417    82           81
  G              T               701    193          180
                 C               168    37           40
                 Total N         3886   1073         930
                 CMH                    10.62        2.69
                 df                     2            2
                 CMH *p*-value          **0.0011**   0.1007

*The results for SZ remained significant (*p* = 0.0011) while combined results of SZ and BD were also significant (not shown, *p* = 0.001)*.

In summary, when SZ and BD were compared to combined controls from GAIN and WTCCC2 datasets, there was weak evidence of association after correction for MDS as well as following the removal of stratification effect of a major ethnic defining haplogroup SNP. The present findings suggest that similar frequencies of SZ or BD were found at major haplogroup specific EA mtSNPs, while more sporadically occurring mtSNPs, T195C and T16519C, in the hypervariable region showed preliminary associations to SZ, and pooled SZ and BD.

Discussion
==========

Common deletion
---------------

We confirmed an increase in brain levels of the 4,977 bp mtDNA common deletion previously reported in BD, aging, and sex (Kato et al., [@B30]; Fuke et al., [@B20]). There was no difference in the common deletion in SZ compared to controls which is also consistent with prior reports (Kato et al., [@B30]; Fuke et al., [@B20]). The 4,977 bp common deletion accumulated with age in brain compared to blood as previously reported (Corral-Debrinski et al., [@B13]; Bender et al., [@B6]; Kraytsberg et al., [@B35]). We also showed that in advanced aging, the levels can remain low in blood while reaching high levels in brain, particularly in regions such as the SN, CAUN, and putamen. The mtDNA common deletion is an example of a somatic mutation that can reach fairly high levels in some brain regions while remaining relatively absent in other brain regions (CB and thalamus) and in blood.

The levels of common deletion vary significantly across brain regions, and are particularly high in mesostriatal and mesolimbic regions such as the SN, putamen, NACC, CAUN, and amygdala (Figure [1](#F1){ref-type="fig"}; Table S2 in Supplementary Material) as shown before in post-mortem brains (Corral-Debrinski et al., [@B13]; Soong et al., [@B59]; Meissner et al., [@B41]). Previous reports have also shown high levels of common deletion in the SN of both aged controls and Parkinson's patients (Bender et al., [@B6]; Kraytsberg et al., [@B35]). Similarly, we also observed high levels of common deletion in some striatal-nigral structures, such as the SN, CAUN, and putamen and to a lesser extent the NACC, innervated and populated by dopaminergic neurons. Other regions such as the cerebellum, with unknown dopamine innervations, had a significantly lower accumulation of the common deletion in the same subjects (Figure [2](#F2){ref-type="fig"}). The regional susceptibility to accumulation of the common deletion might be in both dopamine and glutamatergic innervated brain regions, a result of excessive ROS due to toxic dopamine metabolites, as well as excess calcium ion flow (Ben-Shachar, [@B7]; Lin and Beal, [@B38]; Trushina and McMurray, [@B64]; Keating, [@B31]; Pivovarova and Andrews, [@B49]; Surmeier et al., [@B61]). Both dopaminergic and glutamatergic neurotransmitter systems have been consistently shown to be involved in psychiatric disorders and our findings of higher accumulation of common deletion levels in heavily dopaminergic and glutamatergic regions in BD and MDD supports the involvement of mitochondrial dysfunction in those disorders as previously suggested (Ben-Shachar, [@B7]; Rezin et al., [@B51]; Kato et al., [@B29]; Verge et al., [@B66]). Further studies of the mechanism of protection and susceptibility to the mtDNA common deletion is required to understand this diverse regional pattern and the functional significance in the aging human brain.

A caveat to measurements of homogenized dissected post-mortem brain regions is the lack of specific cellular phenotypes for the mtDNA common deletion, although it is unlikely that cells with deleterious mutations survived with huge burdens of heteroplasmy. Another issue we could not address in the current study is sub-regional or layer specific differences mtDNA common deletion, or the cell specific differences. While it is possible to use laser capture microdissection to look at separate cells, in post-mortem brain, for clonal expansion possibility, we did not initially perform this analysis, as we were interested in the brain regional distribution of somatic mutations. In the future, with certain regions that show very high common deletion rates, this approach could be very fruitful to pursue, although initial studies capturing cell nuclei are not promising as very few mitochondria are captured from cell bodies (Mamdani, F., personal communication). Important details about patients are not specifically known, for example the exact age of onset, there is only partial information regarding the decade of life when psychotic symptoms began for SZ or mood symptoms for BD. The lifetime medication histories are lengthy, most patients receive at least 5--10 different medications, and we are not aware of what the cumulative effects of those medications are on common deletion levels in brain, although we have proposed to study this relationship. These potential factors could contribute to our results as false negatives or false positives in this study.

mtDNA mutation in the DLPFC
---------------------------

This study found 7 novel and 142 rare homoplasmic mutations that appeared in 23 mtDNA genomes derived from DLPFC (Table S5 in Supplementary Material) and in blood samples also analyzed. Thus, we did not find somatic homoplasmic mutations that differed in brain compared to blood. In this study we focused on homoplasmic mutations with high coverage. Although heteroplasmy was observed, we are currently in the process of validating and analyzing our heteroplasmy findings, to be reported in a future manuscript. Five homoplasmic mutations selected for validation by direct sequencing were confirmed. However, we did observe some false positives with this sequencing approach at some heteroplasmic loci, such as the previously reported A \> C at mtDNA 3492 position, a known sequencing error hotspot (Li et al., [@B36]) that we were unable to confirm by Sanger sequencing or by allele-specific amplification.

Our findings support prior reports that the non-coding hypervariable mtDNA regions have more novel mutations than coding regions (Jazin et al., [@B27]; Mishmar et al., [@B42]; Soares et al., [@B58]). This is of interest for the etiology of psychiatric disorders based upon consideration of the partial contribution from mtDNA variants. Since the rate of introduction of mtDNA variants varies from 2- to 20-fold depending upon coding and non-coding regions of mtDNA genome, the introduction of mtDNA variants has been particularly high in the hypervariable region of mtDNA through the world population (Cavelier et al., [@B12]). In fact, the T16519C is the most frequent variant that occurs world-wide, for which we have found a preliminary association (Soares et al., [@B58]). The overall ratio of transition to transversion mutations observed in the present study, 18, is similar to the ratio for human mtDNA of 13.75 previously reported (Brown et al., [@B11]; Tamura and Nei, [@B62]; Belle et al., [@B5]). This preliminary result will require large samples of fully sequenced mtDNA genomes, comparisons between the groups of subjects were not significant due to the small number of total mutations observed per subject.

Schizophrenia and bipolar disorder risk association mtDNA SNP alleles
---------------------------------------------------------------------

In this study we tested the largest sample to date for common mtSNP association with either SZ or BD (*n* = 6,040) using a pool of common controls from GAIN and WTCCC2 and did not observe any significant disease associated alleles following genome-wide correction. Prior reports with smaller sample sizes that have shown trends for association, perhaps did not adequately address population stratification (Kirk et al., [@B32]; Amar et al., [@B1]; Rollins et al., [@B52]). We previously showed in a small sample, that T195C was associated with BD risk (Rollins et al., [@B52]). However, in the current study of 6,040 subjects, we show that T195C is protective for SZ, and in the SZ plus BD pooled analysis. The major haplogroup-defining SNP (A12308G) stratification does not affect the outcome of the protective association of T195C, in this larger sample. These results require replication in an independent study to rule out the possibility of unknown biases accounting for these preliminary GWAS results of 6040 individuals and genotyping by another method to confirm that the presence of a small number of no calls on the Affymetrix 6 chip did not cause this false positive. Others have used a haplogroup analysis to determine differential prevalences of SZ (Mosquera-Miguel et al., [@B43]) or BD in major haplogroups which might be a more sensitive method to avoid effects of unbalanced cases and control ascertainments; however, we chose to look at selected haplogroups in a *post hoc* analysis following our case-control logistic regression analysis covaried with four MDS scores derived from mtSNPs.

While not directly affecting mitochondrial function by altering the protein sequence, several of the nine mtSNPs in the hypervariable region that showed preliminary association, such as 16519, have the highest world-wide mutation rates (Soares et al., [@B58]) and have been previously associated with diseases. T16519C has been associated with cancer (Navaglia et al., [@B45]; Bai et al., [@B3]; Peng et al., [@B46]), diabetes (Liao et al., [@B37]), exercise oxygen consumption (Murakami et al., [@B44]), and other common disorders such as migraine (Zaki et al., [@B74]) in studies of Asian and European cases and controls. This is the first association study of mtDNA 16519T and 16519C variants in psychiatric disorders of BD, while a recent report showed a positive trend for SZ (Mosquera-Miguel et al., [@B43]).

A recent paper did not find an association of T16519C with SZ in a Spanish EA haplogroup case-control analysis (Mosquera-Miguel et al., [@B43]). This study used primarily Spaniards of self-reported EA with SZ (*n* = 942), and a control group consisting of ethnicity-matched Spanish individuals (*N* = 1,231). Although the T16519C, which was studied in only one-half of the subjects was not significant, this SNP had the same magnitude and direction of change in odds-ratio that we report of 0.92 for SZ (Mosquera-Miguel et al., [@B43]). Pooling the T16519C data from Mosquera-Miguel et al. ([@B43]) data with our SZ data shows a simple combined OR = 0.87 (95% CI 0.76--0.98, *p* = 0.027) with a total SZ cases (*n* = 1975) and controls (*n* = 4133) between both studies. The studies are also in agreement with other haplogroup markers such as A12308G, which were not more prevalent in SZ (Mosquera-Miguel et al., [@B43]). As mentioned, there have been reports of T16519C association with metabolic disorders, such as exercise oxygen consumption and diabetes mellitus.

Differences between the current study and Mosquera-Miguel et al. ([@B43]) are that they examined 25 mtDNA SNPs; a smaller number of total subjects especially controls, and did not include a BD case-control analysis. Further, the present study used slightly different mtDNA analyses, correcting possible mtSNP stratification using MDS, preferring this method instead of a formal haplogroup stratification test. Taken together, however, both studies with different approaches, reinforce conceptually that with larger Ns, compared to all prior studies of mtDNA common SNPs, in Southern and Northern EA populations, there was not an overwhelmingly strong association of SZ or BD to common haplogroup-defining SNPs in the coding region of mtDNA. This makes the current T195C and T16519C findings more salient as associated alleles since they are both more sporadically occurring mutations. Importantly, the functionality of both mtSNPs are unknown, T195C is a back mutation to the original ancestral allele which was the 195C, which we find to be protective for both SZ and BD.

Conclusion
==========

In conclusion, the large somatic common deletion was the most variable result in post-mortem brain, highly age-dependent, and replicates many prior reports (Corral-Debrinski et al., [@B13]; Soong et al., [@B59]; Meissner et al., [@B41]). We observed the higher levels of common deletion in mesostriatal and mesolimbic regions such as the SN, putamen, NACC, CAUN, and amygdala, suggesting that oxidative stress mechanisms related to dopamine metabolism to be involved in the accumulation of the common deletion. With multiple caveats stated above, there seems to be some evidence (that requires independent replication) of protective and risk alleles in the hypervariable region of mtDNA, which mutates at a fast rate in the human population. We continue to test the hypothesis that accumulation of large somatic mutations in the coding region is relevant to psychiatric disorders and coupled with sporadic mtSNPs in the hypervariable region these two parts of the molecule may independently exert functional impacts in brain and mitochondrial function.

We also tested whether single point mutations would be found in different brain regions from the same brain. We were unable in this initial study to find evidence for homoplasmic mutations occurring independently across brain. We found the NGS technique to work reliably with some notable exceptions, and have since improved our throughput, by multiplexing 24 samples per lane on a Hi-Seq Illumina instrument, maintaining excellent coverage with 100 bp single reads. We also found evidence that some mtDNA variants are associated with SZ and BD protection or susceptibility at the population level using a large sample of patients and controls and available genotype data.
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